Alexei Siniakov's questions to Kymera Therapeutics Inc (KYMR) leadership • Q3 2024
Question
Speaking for Kripa Devarakonda, Alexei Siniakov of Truist Securities asked if a TYK2 degrader could address efficacy challenges seen with TYK2 inhibitors and whether future trials might enroll patients previously treated with a TYK2 inhibitor.
Answer
CEO Nello Mainolfi asserted that Kymera's degrader aims for a transformative, biologics-like profile by fully blocking TYK2 signaling, unlike inhibitors. CMO Jared Gollob added that initial studies would likely exclude patients who progressed on prior TYK2 inhibitors but might consider them in later-stage trials.